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A B S T R A C T
Objectives: We report the successful treatment of a bloodstream infection caused by Klebsiella
pneumoniae harbouring NDM-1 using aztreonam-ceftazidime-avibactam in a neutropenic patient in
whom colistin and meropenem therapy had previously failed.
Methods: A clinical isolate was evaluated to determine the presence of NDM, TEM, SHV, CTX, and CMY,
and the killing kinetics of aztreonam (ATM; 4 mg/mL), aztreonam-avibactam (ATM-AVI; 4/4 mg/mL), and
colistin (2 and 4 mg/mL) were tested.
Results: ATM-AVI showed in vitro activity against the Klebsiella pneumoniae harbouring NDM-1, whereas
colistin allowed re-growth.
Conclusions: This report supports reconsideration of use of colistin for treatment of infections caused by
K. pneumoniae harbouring NDM. CZA/ATM use should be kept in mind as a treatment option, perhaps
earlier than colistin.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial
Chemotherapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
1. Introduction
Although carbapenems are widely used as first-line agents for
treatment of severe Gram-negative infections, the worldwide
spread of carbapenem-resistant enterobacteria has led clinicians to
a therapeutic dead-end compelling the use of non-β-lactam
antibiotics. New Delhi metallo-β-lactamases (NDM) pose a
particular challenge because of their broad hydrolysing activity
that includes penicillins, cephalosporins, and carbapenems [1].
While aztreonam (ATM) is capable of evading hydrolysis by
metallo-β-lactamases (MBL), serine β-lactamases render ATM
ineffective leading to its combination with β-lactam inhibitors [2].
We present the case of a patient with neutropenia after
haematopoietic cell transplantation (HCT) and bacteraemia caused
by Klebsiella pneumoniae harbouring NDM, in whom therapy with
colistin had failed previously, who was successfully treated with
ceftazidime-avibactam (CZA) plus aztreonam (CZA/ATM).
2. Case presentation
A 35-year-old man from Honduras was referred to a hospital in
Monterrey, Mexico, to undergo evaluation for HCT. The patient
suffered from aplastic anaemia diagnosed 18 months prior to
admission, and was treated with cyclosporin and prednisone
unsuccessfully. He had been hospitalized in Honduras two weeks
before his referral for the treatment of gastrointestinal bleeding.
Upon his arrival in Mexico, the patient was diagnosed with
Salmonella spp. disseminated disease and the HCT was postponed.
He was treated with IV ceftriaxone for seven days and afterward
received PO levofloxacin for another week as an outpatient.
One month later, he underwent preparation for HCT with a
nonmyeloablative regimen (fludarabine, cyclophosphamide, and
anti-thymocyte globulin). One week later, he received total body
irradiation that was followed by the HCT. Only 24 h after the
procedure and with an absolute neutrophil count (ANC) of 1210
cells/mL, the patient had a fever. Blood cultures were obtained, and
imipenem 1 g TID and filgrastim were started, after which
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ther potential infectious and non-infectious causes of fever were
ought.
The patient persisted as febrile, and on day +6, blood cultures
rew K. pneumoniae after 48 h of incubation. The isolate was
usceptible to colistin by broth microdilution (minimum inhibitory
oncentration [MIC] 0.25 mg/mL) and resistant to cefepime,
eftazidime, imipenem, meropenem, levofloxacin, piperacillin/
azobactam, gentamicin, amikacin, trimethoprim/sulfamethoxa-
ole, and CZA by disk diffusion.
The administration of imipenem and vancomycin were stopped,
nd meropenem 2 g TID was started combined with colistin with a
oading dose of 300 mg, after which 150 mg TID followed. The
atter approach was attempted as meropenem MIC was unknown
t the time and, evidence suggests that there is a lower mortality
ate in patients with carbapenemase-producing K. pneumoniae
loodstream infections treated with carbapenem-containing
ombinations [3].
The patient persisted as febrile and neutropenic. The MIC for
eropenem was found to be 32 mg/mL and by day +12 the
ecision was made to stop the meropenem and colistin combina-
ion and start ATM 2 g TID and CZA 20.5 g TID. By day +14, the
atient’s clinical condition improved, he became afebrile, and two
ays later, neutropenia resolved. There were no side effects with
he new antibiotic therapy which was administered for 10 days. He
as discharged and was last seen as an outpatient on day +80 free
f symptoms that suggested infection, but later succumbed to his
aematological disease.
. Results
The carbapenemase-encoding gene (NDM) and the extended-
pectrum β-lactamase encoding genes (TEM, SHV, CTX, and CMY)
ere positive by PCR. NDM-1 was detected by sequencing. KPC,
ES, IMP, VIM, and OXA-48 like genes were not detected [4].
Further laboratory studies included in vitro synergy of AVI and
TM against the K. pneumoniae isolate using an E-test method and
 time to kill assay. AVI was incorporated into Mueller-Hinton agar
lates to a final concentration of 4 mg/mL. Plates were inoculated
ith a K. pneumoniae suspension with an optical density
quivalent to a 0.5 McFarland standard, and an ATM E-test strip
bioMérieux, Marcy-l’Étoile, France) was applied to it, which
The antibiotic concentrations of ATM, AVI, and colistin were
adjusted to the susceptible breakpoint concentration of the
antibiotics recommended by the Clinical and Laboratory Standards
Institute [7]. The killing kinetics of ATM (4 mg/mL), ATM-AVI
(4/4 mg/mL), and colistin (2 and 4 mg/mL) [5] showed that ATM-
AVI had bactericidal activity, decreasing at least three Log at 8 h,
with no regrowth at 48 h of incubation (Fig. 2).
Instead, colistin at 2 mg/mL was initially bactericidal against the
K. pneumoniae strain, and bacterial regrowth was observed after 8
h of incubation. Colistin at 4 mg/mL inhibited the bacterial growth
from 2 h completely.
4. Discussion
Treatment of infections by Enterobacteriaceae harbouring NDM
remains a challenge. In this report, we present evidence of the
successful use of CZA/ATM for management of bacteraemia caused
by K. pneumoniae harbouring NDM in a patient with neutropenia
after an HCT.
The in vitro activity of ATM-AVI has been demonstrated with
promising results [8]. In a study that included 267 Enterobacter-
iaceae positive for MBL genes isolates from 40 countries, all strains
were inhibited with the monobactam/non-β-lactam β-lactamase
inhibitor [2]. The clinical experience is far more limited as the drug
combination is not yet available for clinical use. Currently, there are
two clinical studies under way: a phase III study to determine the
efficacy, safety, and tolerability of ATM-AVI versus best available
therapy in the treatment of infections caused by MBL producing
Gram-negative bacteria (ClinicalTrials.gov registration no.
NCT03580044), and a phase I study aiming to investigate the
safety and pharmacokinetics of CZA/ATM (ClinicalTrials.gov
registration no. NCT03978091). Although ATM-AVI is not available
Fig. 1. Aztreonam MIC for Klebsiella pneumoniae isolate before (A) and after (B) exposure to avibactam.Fig. 2. Time-kill curves showing the effects of unsupplemented broth (control)
and broth supplemented with either aztreonam (4 mg/mL), aztreonam-avibactam
(4/4 mg/mL), or colistin (2 and 4 mg/mL).educed the MIC of ATM from >256 to 0.094 mg/mL. The
ombination of aztreonam-avibactam (ATM-AVI) reduced the MIC
o less than the susceptibility breakpoint of aztreonam (4 mg/mL)
Fig. 1). The killing kinetics of ATM, ATM-AVI, and colistin were
ssessed using a standard time-kill methodology and by viable
acterial counts as previously reported [5,6].418
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patient undergoing solid organ transplant with a previous
infection caused by an NDM-producing K. pneumoniae has been
reported [9].
Regarding treatment with CZA/ATM, there is evidence of 14
patients receiving this combination, with five of them dying as a
result of causes other than infection and the rest achieving clinical
cure [10–13]. Although all these patients had important comor-
bidities or immunosuppression, our case also adds evidence of its
successful use in the context of neutropenia after an HCT, a clinical
scenario that has not been extensively explored [12].
The in vitro activity of ATM with other β-lactamase inhibitors
against MBL-producing Enterobacteriaceae has been reported,
with susceptibility restored for 86%, 50%, and 20% of the isolates
when combined with CZA, amoxicillin-clavulanate, and ceftolo-
zane-tazobactam, respectively [14]. In this report, clavulanate
was as efficient as AVI in many cases. At present, there is no
evidence of an in vivo effect; and an intravenous formulation is
not available.
Meropenem-vaborbactam (MEM-VAB) has also been tested in
vitro in combination with CZA/ATM against MBL-producing
strains. Based on MIC test results, CZA restored ATM susceptibility
in ATM-resistant strains more consistently than MEM-VAB and the
latter proved inactive against an OXA-232 producing strain [15].
Thus, ATM plus MEM-VAB may not be the best option for empiric
treatment of NDM-producing Enterobacteriaceae either.
Because of the lack of available results for use of CZA/ATM
against extensively drug-resistant strains, the treatment of NDM-
producing Enterobacteriaceae with non-β-lactam antibiotics is still
recommended, and polymyxins head the list [1]. Different studies
have evaluated the activity of colistin against K. pneumoniae, with
evidence of prompt initial killing followed by regrowth of strains
(with MICs higher or lower than 2 mg/mL) [16,17]. The case
presented here provides evidence that colistin, in combination
with meropenem may not be the best option to treat infections
caused by K. pneumoniae harbouring NDM. Revision of the current
susceptibility breakpoint for colistin has been suggested, because
no difference in mortality has been detected between colistin-
susceptible and colistin-resistant Enterobacteriaceae when the 2 m
g/mL breakpoint is used [16].
In conclusion, our report supports reconsideration of use of
colistin for treatment of infections caused by K. pneumoniae
harbouring NDM, even in combination with a carbapenem. CZA/
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